Tradestie Institutional Equity Comparison Engine

NUVB vs TSHA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TSHA Overall Edge

TSHA Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Taysha Gene Therapies, Inc. Common Stock (TSHA) driven by superior Momentum & Technical, Options & Structure while NUVB counters with relative strength in Growth & Margin. Fundamentally, NUVB trades at N/M Forward P/E with -61.2% operating margin (+242.6% YoY revenue) versus TSHA at N/M Forward P/E and -2998.0% operating margin (+171.3% YoY). In options structure, NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro) against TSHA sits in BREAKDOWN (34th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
NUVB N/M vs TSHA N/M Fwd P/E
Growth & Margin Winner NUVB
Op Margin -61.2% vs -2998.0% ยท YoY +242.6% vs +171.3%
Momentum & Technical Winner TSHA
1Y -46.9% vs -7.2% ยท 52W Pos 2% vs 7%
Options & Structure Winner TSHA
BREAKDOWN (26th %ile IV) vs BREAKDOWN (34th %ile IV)
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
1M Return -19.15%
1Y Return -46.85%
Forward P/E N/M
Unified AI Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
TSHA NASDAQ
Taysha Gene Therapies, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$3.72
-1.33% 1D
Market Cap $1.2B
1M Return -7.12%
1Y Return -7.23%
Forward P/E N/M
Unified AI Score
49.8 / 100 HOLD
Tech 25.0 Fund 51.0 Flow 69.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NUVB -46.85% TSHA -7.23% Spread: +39.62 pp (TSHA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period NUVB Revenue TSHA Revenue NUVB Op. Margin TSHA Op. Margin Margin Edge
FY2022 N/A $0M N/A -6492.7% TSHA
FY2023 N/A $20M N/A -468.8% TSHA
FY2024 $10M $10M -7527.3% -1097.6% TSHA
FY2025 $60M $10M -338.7% -1130.6% NUVB

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NUVB (5) vs TSHA (3)
Institutional Metric NUVB TSHA Criterion Row Winner
Market Capitalization Scale $1.3B $1.2B Larger Scale NUVB
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +242.6% +171.3% Higher Growth NUVB
Operating Margin (TTM) Profitability -61.2% -2998.0% Higher Margin NUVB
Net Profit Margin Profitability -67.4% 0.0% Higher Margin TSHA
Return on Equity (ROE) Capital Efficiency -49.1% -54.2% Higher ROE NUVB
52-Week Range Position Momentum 2% ($4โ€“$10) 7% ($3โ€“$7) Stronger Trend TSHA
Beta / 30D Volatility Risk Regime 1.52ฮฒ ยท 55% Vol 1.81ฮฒ ยท 52% Vol Lower Realized Risk TSHA
Unified Institutional Score Composite Signal 61.0 / 100 (BUY) 49.8 / 100 (HOLD) Higher Composite NUVB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NUVB vs TSHA Buy Guide
NUVB BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 26th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live NUVB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
TSHA BREAKDOWN
138d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 34th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live TSHA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NUVB nor TSHA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.